Patents by Inventor SUVI TUULA MARJUKKA ORR

SUVI TUULA MARJUKKA ORR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240075153
    Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
    Type: Application
    Filed: October 2, 2023
    Publication date: March 7, 2024
    Inventors: Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
  • Patent number: 11806405
    Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
    Type: Grant
    Filed: September 28, 2022
    Date of Patent: November 7, 2023
    Assignee: Zeno Management, Inc.
    Inventors: Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
  • Publication number: 20230330242
    Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
    Type: Application
    Filed: September 28, 2022
    Publication date: October 19, 2023
    Inventors: Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
  • Publication number: 20230123041
    Abstract: Immunoconjugates of the Formula (I) include a linking group for linking an antibody targeting ligand (Ab) to a drug (D). Embodiments of such immunoconjugates are useful for delivering the drug to selected cells or tissues, e.g., for the treatment of cancer.
    Type: Application
    Filed: July 15, 2022
    Publication date: April 20, 2023
    Inventors: Xiaojun Han, Suvi Tuula Marjukka Orr, Kevin Duane Bunker, Peter Qinhua Huang, Kimberlee Fischer
  • Publication number: 20220089580
    Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
    Type: Application
    Filed: December 7, 2021
    Publication date: March 24, 2022
    Applicant: Pfizer Inc.
    Inventors: Ping Chen, Sujin Cho-Schultz, Judith Gail Deal, Gary Michael Gallego, Mehran Jalaie, Robert Steven Kania, Sajiv Krishnan Nair, Sacha Ninkovic, Suvi Tuula Marjukka Orr, Cynthia Louise Palmer
  • Patent number: 11220494
    Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: January 11, 2022
    Assignee: Pfizer Inc.
    Inventors: Ping Chen, Sujin Cho-Schultz, Judith Gail Deal, Gary Michael Gallego, Mehran Jalaie, Robert Steven Kania, Sajiv Krishnan Nair, Sacha Ninkovic, Suvi Tuula Marjukka Orr, Cynthia Louise Palmer
  • Publication number: 20200354350
    Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
    Type: Application
    Filed: July 29, 2020
    Publication date: November 12, 2020
    Applicant: Pfizer Inc.
    Inventors: Ping Chen, Sujin Cho-Schultz, Judith Gail Deal, Gary Michael Gallego, Mehran Jalaie, Robert Steven Kania, Sajiv Krishnan Nair, Sacha Ninkovic, Suvi Tuula Marjukka Orr, Cynthia Louise Palmer
  • Patent number: 10766884
    Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: September 8, 2020
    Assignee: Pfizer Inc.
    Inventors: Ping Chen, Sujin Cho-Schultz, Judith Gail Deal, Gary Michael Gallego, Mehran Jalaie, Robert Steven Kania, Sajiv Krishnan Nair, Sacha Ninkovic, Suvi Tuula Marjukka Orr, Cynthia Louise Palmer
  • Publication number: 20190330196
    Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
    Type: Application
    Filed: April 23, 2019
    Publication date: October 31, 2019
    Applicant: Pfizer Inc.
    Inventors: Ping Chen, Sujin Cho-Schultz, Judith Gail Deal, Gary Michael Gallego, Mehran Jalaie, Robert Steven Kania, Sajiv Krishnan Nair, Sacha Ninkovic, Suvi Tuula Marjukka Orr, Cynthia Louise Palmer
  • Patent number: 9758538
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1-R11, m, n, and p are defined herein. The novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: September 12, 2017
    Assignee: PFIZER INC.
    Inventors: Ping Chen, Hengmiao Cheng, Gary Michael Gallego, Mehran Jalaie, John Charles Kath, Suvi Tuula Marjukka Orr, Mason Alan Pairish
  • Publication number: 20170015689
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1-R11, m, n, and p are defined herein. The novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
    Type: Application
    Filed: July 13, 2016
    Publication date: January 19, 2017
    Applicant: PFIZER INC.
    Inventors: Ping Chen, Hengmiao CHENG, Gary Michael Gallego, Mehran Jalaie, John Charles Kath, Suvi Tuula Marjukka Orr, Mason Alan PAIRISH
  • Publication number: 20160303125
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Application
    Filed: June 27, 2016
    Publication date: October 20, 2016
    Applicant: PFIZER INC.
    Inventors: SHAWN CABRAL, KENTARO FUTATSUGI, DAVID HEPWORTH, KIM HUARD, DANIEL WEI-SHUNG KUNG, SUVI TUULA MARJUKKA ORR, KUN SONG
  • Patent number: 9440949
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: September 13, 2016
    Assignee: Pfizer Inc.
    Inventors: Shawn Cabral, Kentaro Futatsugi, David Hepworth, Kim Huard, Daniel Wei-Shung Kung, Suvi Tuula Marjukka Orr, Kun Song
  • Patent number: 9260439
    Abstract: The present invention relates to compounds of formula (X) or pharmaceutically acceptable salts thereof, wherein R1-R50, a, b, d, e, f, g, h, i, j, k, l, o, p, q, r, s, t, u, y, and z are defined herein. The novel dihydropyrrolopyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: February 16, 2016
    Assignee: PFIZER INC.
    Inventors: Ping Chen, Hengmiao Cheng, Judith Gail Deal, Gary Michael Gallego, Mehran Jalaie, John Charles Kath, Suvi Tuula Marjukka Orr, Hong Shen, Luke Raymond Zehnder
  • Publication number: 20150291604
    Abstract: The present invention relates to compounds of formula (X) or pharmaceutically acceptable salts thereof, wherein R1-R50, a, b, d, e, f, g, h, i, j, k, l, o, p, q, r, s, t, u, y, and z are defined herein. The novel dihydropyrrolopyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
    Type: Application
    Filed: April 2, 2015
    Publication date: October 15, 2015
    Inventors: Ping CHEN, Hengmiao CHENG, Judith Gail DEAL, Gary Michael GALLEGO, Mehran JALAIE, John Charles KATH, Suvi Tuula Marjukka ORR, Hong SHEN, Luke Raymond ZEHNDER
  • Publication number: 20150259323
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Application
    Filed: March 10, 2015
    Publication date: September 17, 2015
    Applicant: PFIZER INC.
    Inventors: SHAWN CABRAL, KENTARO FUTATSUGI, DAVID HEPWORTH, KIM HUARD, DANIEL WEI-SHUNG KUNG, SUVI TUULA MARJUKKA ORR, KUN SONG